
Gaia Medical Institute LLC Profile last edited on: 4/27/2018
CAGE: 47L81
UEI: H95RP93WA9V5
Business Identifier: Molecular physiology and noninvasive health monitoring Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
505 Coast Boulevard South Suite 104
La Jolla, CA 92037
La Jolla, CA 92037
(858) 459-1722 |
info@gaiamedical.com |
www.gaiamedical.com |
Location: Single
Congr. District: 50
County: San Diego
Congr. District: 50
County: San Diego
Public Profile
Gaia Medical Institute creates noninvasive, easy-to-use tests designed to move diagnostics from the hospital to the field, empowering patients and their caregivers. Organized around advancement of molecular physiology and noninvasive health monitoring, the firm focuses on saliva diagnostics, development of rapid tests, and detection of proteomic biomarkers. The firm's primary research centers around the study of HIV/AIDS, hydration monitoring, post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and post-concussional disorder.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $2,584,232 | |
Project Title: Rapid saliva test for noninvasive diagnostic screening of MCI and dementia | ||||
2022 | 2 | NIH | $2,051,945 | |
Project Title: Saliva Biomarkers for Noninvasive Diagnostics of Acute MTBI in Children | ||||
2018 | 2 | NIH | $1,444,911 | |
Project Title: Rapid Saliva Test for Diagnostics of Neuro-Cognitive Disorder Due to Traumatic Brain Injury (NCDT) | ||||
2018 | 1 | NIH | $225,000 | |
Project Title: Saliva Biomarkers for Predicting Outcome in Pediatric and Adult Patients with Severe and Moderate TBI | ||||
2018 | 2 | NIH | $1,413,301 | |
Project Title: Rapid Oral Test for Therapeutic Response in HIV/Aids Patients |
Key People / Management
Sarka O Southern -- Founder, CEO and Scientific Director
Romuald Arnaud -- Research Associate
Tristan Chambers -- Research Associate
Kelly Ann Gregus -- Research Scientist and Lab Manager
Gerald Lilienthal -- COO
Griffen Stapp -- Controller/CFO
Romuald Arnaud -- Research Associate
Tristan Chambers -- Research Associate
Kelly Ann Gregus -- Research Scientist and Lab Manager
Gerald Lilienthal -- COO
Griffen Stapp -- Controller/CFO
Company News
There are no news available.